

*Psychedelics in the Treatment of Substance Use Disorders: What Clinicians Need to Know*  
Accreditation and Designation Statements

**Accreditation Statement**



In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

**Target Audience Statement**

This activity was designed for physicians and other healthcare professionals and is designated for learners in the following ways:

**Physician Designation Statement**

American Academy of Addiction Psychiatry designates this enduring material activity for a maximum of 1.5 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Other Health Professionals Designation Statement**

Participants will receive a Certificate of Attendance stating this program is designated for 1.5 *AMA PRA Category 1 Credits*<sup>™</sup>. This credit is accepted by the AANP and the AAPA.

***Credits subject to change***

**Learning Objectives**

At the conclusion of this session, participants will

- Review and examine the latest clinical data investigating the use of psychedelics to treat various substance use disorders, including the limitations of the data.
- Describe the subjective experiences of psychedelics as reported by clinical trial participants.
- Determine the rationale for studying psychedelic use in the context of psychotherapy.
- Examine the risks and benefits of utilization in patient therapy.
- Provide tools to communicate with patients about risks and informed consent.